freestyle libre flash glucose monitoring system calibration

Mean HbA1c significantly reduced from baseline (10.8%) to 3 months (9.8%, p 9%, mean HbA1c was significantly reduced from baseline (11.7%) to 3 months (10.3%, p 9%). Resultsġ,307 patients were included, with a mean age of 11.1 years (standard deviation 3.6 years). Patient demographics were collected from electronic health records. HbA1c (%) was measured at baseline and 3, 6, and 9 months. The flash glucose monitoring sensor was attached to the back of the upper arm at the baseline visit. Patients were excluded if they had used flash glucose monitoring or other interstitial glucose monitoring systems in the past 3 months, were pregnant, or had existing hemoglobinopathies.

These patients were first-time users of any kind of continuous glucose monitoring system, aged 4–18 years, and received insulin via multiple dose injection or continuous subcutaneous insulin infusion for at least 6 months prior to study start. Patients were subjected to flash glucose monitoring using the FreeStyle ® Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, UK), an intermittently scanned continuous glucose monitoring device approved by the Conformité Européenne in 2014. MethodsĪ retrospective cohort study of pediatric and adolescent type 1 diabetes mellitus patients randomly sampled from 32 Ministry of Health diabetes centers across Saudi Arabia was performed. This study aimed to measure the effect of continuous glucose monitoring on glycated hemoglobin (HbA1c) at 3, 6, and 9 months following sensor insertion.

Continuous glucose monitoring enables easy and effective monitoring of interstitial glucose around the clock and hence improves glycemic control. Measurement of glucose levels is the mainstay method of ensuring good glycemic control and preventing complications associated with uncontrolled diabetes.

Freestyle libre flash glucose monitoring system calibration